Rajat Bhushan
Baton Rouge, LANPI 1881709657
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,193 of the $80,081 with a category attached, or 83.9%. 40 manufacturers reported payments, led by AstraZeneca at 53.7% of the total. Reporting peaked in 2019 at $54,401 and has fallen 99.9% since, to $81 in 2025.
Across 529 payments — averaging $151.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$43K
- Sanofi-aventis U.S. LLC$17K
- Johnson & Johnson$14K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- AbbVie$797
- Novo Nordisk$591
- plus $4K from 34 others
What the payments were for
- Consulting fees$3750%
- Speaking & faculty fees$67,19384%
- Travel & lodging$2,6043%
- Food & beverage$9,82212%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 208 | $238,130 |
| MounjaroTirzepatide | 152 | $165,525 |
| FarxigaDapagliflozin Propanediol | 81 | $74,847 |
| Xigduo XrDapaglifloz Propaned/Metformin | 45 | $39,837 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $36,124 |
| TrintellixVortioxetine Hydrobromide | 34 | $29,424 |
| LinzessLinaclotide | 28 | $29,373 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $26,500 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 33 | $25,163 |
| JardianceEmpagliflozin | 36 | $25,157 |
| Repatha SureclickEvolocumab | 20 | $21,196 |
| ViberziEluxadoline | 12 | $18,125 |
| SynthroidLevothyroxine Sodium | 193 | $16,581 |
| VascepaIcosapent Ethyl | 41 | $16,481 |
| XyostedTestosterone Enanthate | 25 | $15,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $591 | $242,678222 claims |
| Lilly USA, LLCMounjaro | $92 | $165,525152 claims |
| AstraZenecaFarxiga | $42,975 | $74,84781 claims |
| AbbVieLinzess, Viberzi, Synthroid, Fetzima | $797 | $69,281244 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Glyxambi | $160 | $64,27385 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,026 | $29,42434 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $16,503 | $26,50024 claims |
| Johnson & JohnsonInvokana, Xarelto | $14,098 | $19,10428 claims |
| Antares Pharma, Inc.Xyosted | $23 | $15,26225 claims |
| Astellas Pharma US IncMyrbetriq | $90 | $10,48024 claims |
| Amneal Pharmaceuticals LLCUnithroid | $300 | $1,94136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.